Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Renaissance 2: Estudio SPN-817 Fase 2, doble ciego, controlado con placebo en adultos con ataques de inicio focal

30 de septiembre de 2026 actualizado por: Supernus Pharmaceuticals, Inc.

Renaissance 2: un estudio doble ciego, aleatorizado, controlado con placebo, multicéntrico y de grupo paralelo para evaluar la eficacia, la seguridad y la tolerabilidad de SPN-817 en adultos con ataques focales de inicio focal

This is a Phase 2 double-blind, randomized, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy, safety, and tolerability of SPN-817 in adults with focal onset seizures.

Descripción general del estudio

Estado

Reclutamiento

Intervención / Tratamiento

Descripción detallada

This is a Phase 2 double-blind, randomized, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy, safety, and tolerability of SPN-817 administered as an adjunctive treatment in adults with focal onset seizures that have previously failed at least 2 anti-seizure medication (ASM) regimens. Participants will be taking 1 to 4 ASMs, with at least 4 seizures during the 6-week Screening Period. Following the Screening Period, eligible participants will be randomized 2:1 to SPN-817 (3.0-4.0 mg BID) or placebo and begin the Titration Period (8-10 weeks). In both treatment groups, open-label ondansetron (or another concomitant medication to assess pharmacological approaches to managing cholinergic adverse events [AEs]) will be taken (8 mg oral [PO]) prophylactically approximately 30 minutes before each study medication (SM) dose (ie, BID) during the Titration Period as an antiemetic. After the target dose of 3.0-4.0 mg BID is reached, participants will enter the Maintenance Period (14 weeks). Ondansetron (or another concomitant medication to assess pharmacological approaches to managing cholinergic AEs) may be taken as needed as either a preventative or therapeutic antiemetic during the Maintenance Period. Participants who complete the Maintenance Period will have the opportunity to enroll in a separate open-label study for continued treatment with SPN-817. Participants who do not enroll in the open-label study will undergo a Tapering Period (up to 4 weeks) and a follow-up safety phone call.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

216

Fase

  • Fase 2

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Navid Saeidi, MS
  • Número de teléfono: 240-403-5328
  • Correo electrónico: nsaeidi@supernus.com

Copia de seguridad de contactos de estudio

Ubicaciones de estudio

    • Queensland
      • Herston, Queensland, Australia, 4029
        • Reclutamiento
        • Royal Brisbane and Women's Hospital
    • South Australia
      • Adelaide, South Australia, Australia, 5000
        • Reclutamiento
        • Royal Adelaide Hospital
    • Victoria
      • Clayton, Victoria, Australia, 3168
        • Reclutamiento
        • Monash Medical Centre
      • Fitzroy, Victoria, Australia, 3065
        • Reclutamiento
        • St. Vincent's Hospital Melbourne
      • Melbourne, Victoria, Australia, 3004
        • Reclutamiento
        • The Alfred Hospital
      • Parkville, Victoria, Australia, 3052
        • Reclutamiento
        • Royal Melbourne Hospital
    • Western Australia
      • Nedlands, Western Australia, Australia, 6009
        • Reclutamiento
        • The Perron Institute for Neurological and Translational Science
      • Blagoevgrad, Bulgaria, 2700
        • Reclutamiento
        • Multiprofile Hospital for Active Treatment PULS
      • Pleven, Bulgaria, 5809
        • Reclutamiento
        • Medical Center (MC) Academica
      • Rousse, Bulgaria, 7012
        • Reclutamiento
        • Medical Center - Teodora EOOD
      • Sofia, Bulgaria, 1113
        • Reclutamiento
        • Multiprofile Hospital for Active Treatment in Neurology and Psychiatry "Sveti Naum" EAD
    • Sofia-Grad
      • Sofia, Sofia-Grad, Bulgaria, 1431
        • Reclutamiento
        • University Multiprofile Hospital for Active Treatment Aleksandrovska, Clinic for Neurology Diseases
    • Arizona
      • Phoenix, Arizona, Estados Unidos, 85004
        • Reclutamiento
        • Xenoscience
      • Phoenix, Arizona, Estados Unidos, 85006
        • Reclutamiento
        • Banner University Medical Center-Phoenix
      • Tucson, Arizona, Estados Unidos, 85724
        • Reclutamiento
        • University of Arizona College of Medicine - Tucson
      • Tucson, Arizona, Estados Unidos, 85718
        • Reclutamiento
        • Center for Neurosciences
    • Arkansas
      • Little Rock, Arkansas, Estados Unidos, 72205
        • Reclutamiento
        • Clinical Trials, Inc
    • California
      • Los Angeles, California, Estados Unidos, 90048
        • Reclutamiento
        • Clinical Research Institute
      • Mission Hills, California, Estados Unidos, 91345
        • Reclutamiento
        • Access Community Clinical Trials
      • Orange, California, Estados Unidos, 92868
        • Reclutamiento
        • University of California, Irvine
      • West Hills, California, Estados Unidos, 91307
        • Reclutamiento
        • Focus Clinical Research
    • Connecticut
      • New Haven, Connecticut, Estados Unidos, 06510
        • Reclutamiento
        • Yale University
    • Florida
      • Gulf Breeze, Florida, Estados Unidos, 32561
        • Reclutamiento
        • Northwest Florida Clinical Research Group, LLC
      • Kissimmee, Florida, Estados Unidos, 34744
        • Reclutamiento
        • Ilumina Medical Research
      • Miami, Florida, Estados Unidos, 33136
        • Reclutamiento
        • University of Miami
      • Miami, Florida, Estados Unidos, 33133
        • Reclutamiento
        • Visionary Investigators Network
      • Orlando, Florida, Estados Unidos, 32806
        • Terminado
        • Research Institute of Orlando, LLC
      • Port Charlotte, Florida, Estados Unidos, 33952
        • Reclutamiento
        • Medsol Clinical Research Center
        • Contacto:
      • Port Saint Lucie, Florida, Estados Unidos, 34990
        • Reclutamiento
        • Cleveland Clinic Florida Martin Health
    • Illinois
      • Springfield, Illinois, Estados Unidos, 62702
        • Reclutamiento
        • Southern Illinois University School of Medicine
    • Kentucky
      • Louisville, Kentucky, Estados Unidos, 40223
        • Reclutamiento
        • University of Louisville Physicians
    • Louisiana
      • Covington, Louisiana, Estados Unidos, 70433
        • Reclutamiento
        • Neurocare of Louisiana
      • New Orleans, Louisiana, Estados Unidos, 70121
        • Suspendido
        • Ochsner Clinic Foundation
    • Maryland
      • Baltimore, Maryland, Estados Unidos, 21287
        • Reclutamiento
        • Johns Hopkins University
      • Bethesda, Maryland, Estados Unidos, 20817
        • Reclutamiento
        • Mid Atlantic Epilepsy and Sleep Center
    • Michigan
      • Detroit, Michigan, Estados Unidos, 48201
        • Reclutamiento
        • Wayne State University - Detroit Medical Center
    • New Jersey
      • Hackensack, New Jersey, Estados Unidos, 07601
        • Reclutamiento
        • Northeast Regional Epilepsy Group - Hackensack
      • Neptune City, New Jersey, Estados Unidos, 07753
        • Reclutamiento
        • Hackensack Meridian Health Jersey Shore University Medical Center
    • New York
      • Albany, New York, Estados Unidos, 12208
        • Reclutamiento
        • Albany Medical Center
      • Amherst, New York, Estados Unidos, 14226
        • Reclutamiento
        • Dent Neurologic Institute
      • New York, New York, Estados Unidos, 10021
        • Reclutamiento
        • Northwell Health - Lenox Hill
      • Rochester, New York, Estados Unidos, 14618
        • Reclutamiento
        • University of Rochester Medical Center
    • North Carolina
      • Asheville, North Carolina, Estados Unidos, 28806
        • Reclutamiento
        • Asheville Neurology Specialists
      • Charlotte, North Carolina, Estados Unidos, 28211
        • Reclutamiento
        • OnSite Clinical Solutions, LLC
    • Ohio
      • Cleveland, Ohio, Estados Unidos, 44195
        • Reclutamiento
        • Neurology Institute Epilepsy Center of Cleveland Clinic
    • Pennsylvania
      • Philadelphia, Pennsylvania, Estados Unidos, 19107
        • Reclutamiento
        • Thomas Jefferson University
    • Tennessee
      • Nashville, Tennessee, Estados Unidos, 37232
        • Reclutamiento
        • Vanderbilt University Medical Center
    • Texas
      • El Paso, Texas, Estados Unidos, 79912
        • Reclutamiento
        • Advanced Neurology Epilepsy and Sleep Center/ANESC Research
      • Frisco, Texas, Estados Unidos, 75034
        • Reclutamiento
        • Stryde Research
      • Houston, Texas, Estados Unidos, 77030
        • Reclutamiento
        • UT Health Houston
    • Virginia
      • McLean, Virginia, Estados Unidos, 22101
        • Reclutamiento
        • Medstar Health Research Institute
      • Budapest, Hungría, 1125
        • Reclutamiento
        • Flash Clinic
      • Budapest, Hungría, 1145
        • Reclutamiento
        • SE, Idegsebeszeti es Neurointervencios Klinika, Epilepszia Centrum
      • Lublin, Polonia, 20-064
        • Reclutamiento
        • NZOZ NEUROMED M. and M. Nastaj Spółka Partnerska
    • Lesser Poland Voivodeship
      • Krakow, Lesser Poland Voivodeship, Polonia, 30-727
        • Reclutamiento
        • Pratia MCM Kraków
    • Maloplski
      • Krakow, Maloplski, Polonia, 30-363
        • Reclutamiento
        • Centrum Medyczne Plejady
    • Masovian Voivodeship
      • Warsaw, Masovian Voivodeship, Polonia, 01-684
        • Reclutamiento
        • Centrum Medyczne NeuroProtect
      • Warsaw, Masovian Voivodeship, Polonia, 02-172
        • Reclutamiento
        • TZ Clinical Research powered by Pratia
      • Warsaw, Masovian Voivodeship, Polonia, 02-952
        • Reclutamiento
        • Neurosphera
    • Pomeranian Voivodeship
      • Gdynia, Pomeranian Voivodeship, Polonia, 81-537
        • Reclutamiento
        • Synexus Polska Sp. z o. o. Oddział w Gdyni
      • Sopot, Pomeranian Voivodeship, Polonia, 81-735
        • Suspendido
        • Terra Centrum Leczenia
    • Silesian Voivodeship
      • Katowice, Silesian Voivodeship, Polonia, 40-123
        • Reclutamiento
        • NZOZ Wielospacjalistyczna Poradnia Lekarska Synapsis
      • Katowice, Silesian Voivodeship, Polonia, 40-650
        • Reclutamiento
        • Novo-Med Zieliński i Wsp. Sp.J.

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 70 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  1. Diagnosis of treatment-resistant focal epilepsy as adjudicated by the Epilepsy Study Consortium, Inc (ESCI);
  2. Failed to achieve sustained seizure freedom after ≥2 tolerated, appropriately chosen, and adequately dosed ASM drug schedules;
  3. Able to keep accurate Seizure electronic diaries [eDiaries] (with the aid of a caregiver as needed);
  4. Has a body mass index (BMI) between 18.0 and 40.0 kg/m2;
  5. Treatment with a stable dose of 1 to 4 current ASMs for ≥28 days prior to screening. If following a diet plan along with the ASM, the participant should have been on a stable diet plan for at least 1 month prior to Visit 1. The diet plan should be maintained throughout the duration of the study;
  6. At least 4 clinically observable focal onset seizures accepted by the ESCI prior to the first dose of SM (during the days of baseline Seizure electronic diary [eDiary] data collection) and no more than a consecutive 21-day period that was free of these seizures. To be eligible for the study, participants must comply with the eDiary on at least 80% of the days of baseline data collection;

Exclusion Criteria:

  1. Has taken huperzine A within the past 6 months;
  2. Prior diagnosis of combined focal and generalized epilepsy syndrome as evidenced by severe developmental delay and multiple seizure types and confirmed by electroencephalography (EEG) (eg, Lennox-Gastaut syndrome). Participants should also be excluded in case of nondiagnostic information;
  3. History of or current nonepileptic events that could be confused by the participant and/or study staff as epileptic seizures;
  4. Only has seizures that are difficult to count; for example, seizures that are not clinically observable;
  5. History of uncountable seizures, such as seizures that happen in a cluster that are too rapid to be counted individually;
  6. History of status epilepticus within 6 months prior to screening;
  7. Vagus nerve stimulation, deep brain stimulation, responsive neurostimulator system, or other neurostimulation for epilepsy device implanted or activated within 1 year prior to screening; or epilepsy surgery within 1 year prior to screening. Stimulation parameters for devices must have been stable for at least 3 months prior to Screening. Battery change for any epilepsy devices will be allowed; however, stimulation parameters must remain stable during the duration of the study;
  8. Any suicidal behavior or suicidal ideation related to item 4 (active suicidal ideation with some intent to act, without specific plan) or item 5 (active suicidal ideation with specific plan and intent) based on the C-SSRS assessment in the 1 year before screening; a suicide attempt in the last 2 years before screening; or more than 1 lifetime suicide attempt;
  9. Chronic concomitant therapy with non-ASMs that have potent cholinergic (central or peripheral) or potent central (only) anticholinergic pharmacology.
  10. History of >2 allergic reactions to an ASM or 1 serious hypersensitivity reaction to an ASM;
  11. Any other reason which, in the opinion of the Investigator, would prevent the participant from taking part in the study.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Cuadruplicar

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: SPN-817

SPN-817, bid

SPN-817 starting at 0.25 mg bid up to 4.00 mg bid

Comparador de placebos: Placebo

Placebo, bid

Placebo, bid

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Percent change (PCH) from baseline in focal onset seizure frequency per 28 days over the Maintenance Period
Periodo de tiempo: Baseline and Maintenance Period (Maintenance Week 1-14)

Percent change in 28-day frequency of focal seizures during the 14 week Maintenance Period relative to baseline

Baseline and Maintenance Period (Maintenance Week 1-14)

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Proportion of subjects experiencing ≥50% reduction in focal seizure frequency per 28 days from baseline
Periodo de tiempo: Baseline and Maintenance Period (Maintenance Week 1-14)

Greater than or equal to 50% reduction in 28-day frequency of focal seizures during the 14 week Maintenance Period relative to baseline.

Baseline and Maintenance Period (Maintenance Week 1-14)
PCH from baseline in focal onset seizure frequency per 28 days over the entire Treatment Period
Periodo de tiempo: Baseline through Titration Week 1 up to Week 10 and Maintenance Weeks 1-14

Percent change in 28-day frequency of focal seizures during the entire Treatment Period (Titration Period + Maintenance Period) relative to baseline

Baseline through Titration Week 1 up to Week 10 and Maintenance Weeks 1-14
Proportion of subjects experiencing ≥50% reduction in focal seizure frequency per 28 days from baseline
Periodo de tiempo: Baseline through Titration Week 1 up to Week 10 and Maintenance Weeks 1-14

Greater than or equal to 50% reduction in 28-day frequency of focal seizures during the Treatment Period (Titration Period + Maintenance Period) relative to baseline.

Baseline through Titration Week 1 up to Week 10 and Maintenance Weeks 1-14
Longest seizure-free interval over the entire Treatment Period
Periodo de tiempo: Baseline through Titration Week 1 up to Week 10 and Maintenance Weeks 1-14

The longest intervals in days between two seizures during the entire Treatment Period.

Baseline through Titration Week 1 up to Week 10 and Maintenance Weeks 1-14
Incidence of treatment-emergent adverse events (TEAEs)
Periodo de tiempo: Baseline through Titration Week 1 up to Week 10, Maintenance Weeks 1-14, and Tapering Period up to Week 4

The percent of subjects who took at least one dose of SPN-817 and reported at least one adverse event during SPN-817 treatment.

Baseline through Titration Week 1 up to Week 10, Maintenance Weeks 1-14, and Tapering Period up to Week 4

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Director de estudio: Maciej Gasior, MD, PhD, Supernus Pharmaceuticals, Inc.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

30 de diciembre de 2024

Finalización primaria (Estimado)

1 de agosto de 2027

Finalización del estudio (Estimado)

1 de agosto de 2027

Fechas de registro del estudio

Enviado por primera vez

16 de enero de 2025

Primero enviado que cumplió con los criterios de control de calidad

27 de enero de 2025

Publicado por primera vez (Actual)

29 de enero de 2025

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

1 de octubre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

30 de septiembre de 2026

Última verificación

1 de septiembre de 2026

Más información

Términos relacionados con este estudio

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir